Detalhe da pesquisa
1.
Ten-year clinical outcomes from a randomized trial comparing new-generation everolimus-eluting stent versus first-generation Sirolimus-eluting stent: Results from the RESET extended study.
Catheter Cardiovasc Interv
; 102(4): 594-607, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37545171
2.
Randomized comparison between 2-link cell design biolimus A9-eluting stent and 3-link cell design everolimus-eluting stent in patients with de novo true coronary bifurcation lesions: the BEGIN trial.
Heart Vessels
; 34(8): 1297-1308, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30859377
3.
Second-Generation vs. First-Generation Drug-Eluting Stents in Patients With Calcified Coronary Lesionsã- Pooled Analysis From the RESET and NEXT Trials.
Circ J
; 82(2): 376-387, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28978818
4.
Development of new risk score for pre-test probability of obstructive coronary artery disease based on coronary CT angiography.
Heart Vessels
; 30(5): 563-71, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24770610
5.
A novel HCN4 mutation, G1097W, is associated with atrioventricular block.
Circ J
; 78(4): 938-42, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24492017
6.
Effectiveness of the direct renin inhibitor, aliskiren, in patients with resistant hypertension.
Int Heart J
; 54(2): 88-92, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23676368
7.
Lipocalin-type prostaglandin D synthase is associated with coronary vasospasm and vasomotor reactivity in response to acetylcholine.
Circ J
; 75(4): 897-904, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21325722
8.
7-Year Outcomes of a Randomized Trial Comparing the First-Generation Sirolimus-Eluting Stent Versus the New-Generation Everolimus-Eluting Stent: The RESET Trial.
JACC Cardiovasc Interv
; 12(7): 637-647, 2019 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30947938
9.
Impact of Angiographic Residual Stenosis on Clinical Outcomes After New-Generation Drug-Eluting Stents Implantation: Insights From a Pooled Analysis of the RESET and NEXT Trials.
J Am Heart Assoc
; 7(13)2018 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29960987
10.
The association between morning hypertension and metabolic syndrome in hypertensive patients.
Hypertens Res
; 29(10): 783-8, 2006 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17283865
11.
Impact of paraoxonase polymorphism (Q192R) on endothelial function in intact coronary circulation.
Hypertens Res
; 29(6): 417-22, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16940704
12.
Plasma level of oxidized low-density lipoprotein is an independent determinant of coronary macrovasomotor and microvasomotor responses induced by bradykinin.
J Am Coll Cardiol
; 44(2): 451-7, 2004 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-15261947
13.
Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients.
J Am Coll Cardiol
; 41(8): 1373-9, 2003 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-12706934
14.
Brachial artery flow-mediated vasodilation is correlated with coronary vasomotor and fibrinolytic responses induced by bradykinin.
Hypertens Res
; 28(1): 59-66, 2005 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-15969256
15.
Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer: NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial.
Circ Cardiovasc Interv
; 8(10)2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26446596
16.
Angiotensin-converting enzyme insertion/deletion polymorphism modulates coronary release of tissue plasminogen activator in response to bradykinin.
Hypertens Res
; 27(1): 39-45, 2004 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-15055254
17.
Endothelial modulation and tolerance development in the vasorelaxant responses to nitrate of rabbit aorta.
Life Sci
; 73(24): 3083-94, 2003 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-14550849
18.
Long-term clinical outcomes after everolimus- and sirolimus-eluting coronary stent implantation: final 3-year follow-up of the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial.
Circ Cardiovasc Interv
; 7(3): 343-54, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24803436
19.
Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial.
J Am Coll Cardiol
; 62(3): 181-190, 2013 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-23684673
20.
Whole-body periodic acceleration enhances brachial endothelial function.
Circ J
; 72(1): 139-43, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18159115